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ABSTRACT: The analytical characterization of biopharmaceuticals is a
fundamental step in the early stages of development and prediction of
their behavior in bioprocesses. Protein aggregation in particular is a
common issue as it aﬀects all stages of product development. In the
present work, we investigate the stability and the aggregation kinetics of
A33Fab, a therapeutically relevant humanized antibody fragment at a
wide range of pH, ionic strength, and temperature. We show that the
propensity of A33Fab to aggregate under thermally accelerated
conditions is pH and ionic-strength dependent with a stronger
destabilizing eﬀect of ionic strength at low pH. In the absence of
added salts, A33Fab molecules appear to be protected from aggregation
due to electrostatic colloidal repulsion at low pH. Analysis by
transmission electron microscopy identiﬁed signiﬁcantly diﬀerent
aggregate species formed at low and high pH. The correlations between
apparent midpoints of thermal transitions (Tm,app values), or unfolded mole fractions, and aggregation rates are reported here to
be signiﬁcant only at the elevated incubation temperature of 65 °C, where aggregation from the unfolded state predominates. At
all other conditions, particularly at 4−45 °C, aggregation of A33 Fab was predominantly from a native-like state, and the kinetics
obeyed Arrhenius behavior. Despite this, the rank order of aggregation rates observed at 45 °C, 23 and 4 °C still did not correlate
well to each other, indicating that forced degradation at elevated temperatures was not a good screen for predicting behavior at
low temperature.
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■ INTRODUCTION
Therapeutic proteins have become one of the fastest growing
classes of approved biopharmaceutical products. While
monoclonal antibodies (mAbs) have been used for almost
three decades, novel classes of therapeutic antibodies, such as
antigen-binding fragments (Fabs), single-chain variable frag-
ments (ScFv) and single-domain antibodies (sdAb), have
recently yielded promising results in preclinical developments
and clinical trials.1 For example, Fabs are now used in the
treatment of a wide variety of diseases such as rheumatoid
arthritis, multiple sclerosis, and thrombosis.2 High purity and
stable formulations are key attributes to the development and
the manufacturing of such molecules. The robustness of the
formulations against external stress factors is crucial as
therapeutic proteins are exposed to various types of stress
such as temperature, pH, salts, mechanical stress, surface
interaction, and oxidation.3−5 Protein aggregation is a common
issue faced during manufacturing as it aﬀects all stages from the
production to the ﬁnal administration. Indeed, biotherapeutic
aggregation not only reﬂects a loss of valuable product, but also
more importantly can lower the potency and eﬃcacy of the
molecule as well as a higher risk of adverse immunogenicity.6−8
Therefore, the prediction or control of protein aggregation
during the production and storage of a biotherapeutic drug is
much needed.6,9,10
Eﬀorts to address the challenge of predicting or controlling
protein aggregation currently align to two converging
approaches. The ﬁrst aims at gaining a more detailed
understanding of the molecular and kinetic mechanisms of
protein aggregation, and the eﬀects of external stresses, to
enable the improved design of processing and formulation
conditions that minimize the amount and size of aggregates in a
ﬁnal product. Lumry and Eyring11 ﬁrst proposed a mechanistic
model of protein aggregation in which reversible changes of the
native structure were followed by irreversible aggregation: N⇔
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U → F. Since then, multiple models for protein aggregation
have been proposed illustrating a number of distinct pathways
that could be summarized in ﬁve general mechanisms: (1) the
reversible association of the native monomer, (2) the
aggregation of conformationally altered monomers, (3) the
aggregation of chemically modiﬁed monomers, (4) nucleation-
controlled aggregation, and (5) surface-induced aggrega-
tion.12,13 However, the relative roles and interplay of these
mechanisms, during the formulated storage and biomanufactur-
ing of therapeutic proteins, are not yet fully understood.
Previously, changes in the mechanism of aggregate growth have
been observed as the solution conditions are varied.14 Clearly
then, many more studies are required to determine whether
such behavior is general or whether the predominant
mechanisms are in any way related to particular conditions,
bioprocesses, protein families, or protein structures.
The second approach uses rapidly measurable properties of a
protein or process as indicators for predicting the propensity to
aggregate. For example, apparent conformational stability
measurements such as Tm,app, or forced degradation tests at
elevated temperature or agitation, are currently the most
popular indicators used to design new proteins and their
formulations for storage stability to aggregation. The inﬂuences
of conformational stability and external stresses on protein
aggregation have been studied extensively, though mostly
focused on disease-related protein ﬁbrillation13,15−18 or anti-
body aggregation,14,19−24 and the extent to which apparent
conformational stability correlates to aggregation rates remains
hotly debated.24−26 Proteins can fully or partially lose their
native structure upon destabilization by temperature, pressure,
chaotropes, or mutations, allowing the exposure of buried
regions, which in turn leads to aggregation.13,27 Several
methods have also attempted to predict the relative aggregation
propensity or solubility from protein sequence, such as
TANGO,28 PASTA,29 and AGGRESCAN,30 or from native
protein structure features such as positively charged surface
patches,27,31,32 structural classiﬁcation,32 and the packing
density and polarity of buried interfaces.27 These methods
agree that good predictions of aggregation propensity or
solubility require structural information about the protein,
particularly the properties and stabilities of localized surface
features or substructures that would lead to aggregation from
near-native forms. Notably, however, none of them has relied
upon calculations of global conformational stability to
unfolding, suggesting that the common use of Tm,app-values
for predicting the stability of therapeutic protein formulations
to aggregation may be an oversimpliﬁcation or perhaps relevant
only when aggregation occurs from highly unfolded states.
Changes in the non-native aggregation mechanisms of an
antistreptavidin IgG1 were recently determined over a wide
range of pH values and NaCl under accelerated conditions.14
Aggregation rates were inﬂuenced mainly by conformational
stability (unfolding) of at least the Fab regions, which
outweighed electrostatic colloidal attractions, whereas the
aggregate growth mechanism was aﬀected by changes in
electrostatic colloidal interactions. In another study,19 the ionic
strength was reported to have relatively minor qualitative eﬀects
on IgG1 unfolding, while pH had large eﬀects. Colloidal
interactions between native monomeric antibodies were also
shown to be sensitive to both pH and ionic strength and
indicated that electrostatic interactions and nonuniform
surface-charge distributions were important at near-neutral
pH. Meanwhile, Menzen et al.20 reported that repulsive net
charges at low pH increased the colloidal stability of IgG1,
although a reduction of the conformational stability was
observed. However, at neutral conditions and in the presence
of salt, IgG1 unfolding was followed by its the precipitation.
For an IgG2, non-native oligomers were found to be soluble
at pH 5.5 above 15 °C but converted reversibly to visible/
insoluble particles at lower temperatures.21 Lower pH values
yielded only soluble aggregates, whereas higher pH values
resulted in insoluble aggregates. A diﬀerent human IgG2
antibody exhibited a pH-dependent dimer formation under
normal storage conditions (4 °C or 29 °C).22 However, an
inversed pH-dependence was discovered for high molecular
weight aggregate formation at higher temperatures (37 °C).
The diﬀerent stability proﬁles exhibited at the various storage
conditions resulted in nonlinearity of the Arrhenius kinetics for
aggregation. For the pH- and temperature-dependent denatura-
tion of a mouse IgG2, the Fab fragment was shown to be the
least stable to heat treatment, whereas the Fc region was least
stable to decreasing pH.33 Below the ﬁrst unfolding transition,
aggregation was found to be dependent on protein unfolding,
whereby aggregation rates increased with the rate of unfolding
at higher temperatures. The structure of the aggregates formed
also depended on the denaturation method.
Clearly, while some broad generalities are apparent, there is
no robust consensus across diﬀerent IgG isoforms in terms of
the underlying aggregation mechanisms. Furthermore, the
relative inﬂuence of the Fab fragment and its conformational
stability within the IgGs has been examined very little.34,35 A
recent study of the eﬀects of NaCl and pH on conformational
stability, aggregation propensity, and chemical stability of a Fab
showed that increases in NaCl led to enhanced conformational
stability and decreased aggregation rates.36 However, it is not
yet known whether this is a general observation across all Fab
molecules. It is also not clear whether the previously observed
correlations between apparent conformational stability and
aggregation rate for an isolated Fab and for one of the above
IgG1s hold true at all incubation temperatures. In contrast to
full IgGs, data on Fab stability are relatively scarce, yet as they
appear to strongly inﬂuence IgG aggregation, insights on Fab
molecules will greatly aid in our understanding of their role
within the aggregation of full IgGs.
In the present work, we investigated the stability and the
aggregation kinetics of A33Fab, a therapeutically relevant
humanized antibody fragment.37 We demonstrate that the
commonly assumed, but recently debated, relationship between
apparent conformational stability (Tm,app) and aggregation
rate22,24−26,33,36,38 is only signiﬁcant for A33Fab at incubation
temperatures close to the Tm,app, where aggregation from the
unfolded state predominates. We also determined the
aggregation kinetics to obey Arrhenius behavior except where
conditions lead to signiﬁcant unfolding. Finally, in contrast to
the previous study of Fab aggregation,36 we found that for
A33Fab, increased ionic strength was conformationally
destabilizing and increased the rate of aggregation at low pH
values, demonstrating that as for IgGs, diﬀerent sequences
within a protein family can readily modify the relative
inﬂuences of external factors.
■ MATERIALS AND METHODS
Site-Directed Mutagenesis. E. coli strain W3110 contain-
ing plasmid pTTOD A33 IGS2 was provided by UCB (Slough,
UK). The A33Fab37 originally provided was mutated into
A33Fab-C226S (referred to as A33Fab in this manuscript) to
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minimize the dimerization due to the presence of an unpaired
cysteine at position 226. The rational mutagenesis was carried
out using the QuikChange XL site-directed mutagenesis kit
(Stratagene, USA). In-house electro-competent W3110 cells
were used for A33Fab expression and production.
Pilot-Scale A33Fab Production. Starter cultures were ﬁrst
grown in 2xPY complex media containing 10 μg mL−1 of
tetracycline at 37 °C, 200 rpm for 4 h then transferred into
SM6G deﬁned media39 containing 112 g L−1 of glycerol and 10
μg mL−1 of tetracycline and incubated at 30 °C for about 20 h
at 200 rpm. Two liters of this inoculum was transferred into 18
L of SM6G deﬁned media in the 30 L fermenter (BIOSTAT
Cplus, Sartorius, Goettingen, Germany). The dissolved oxygen
tension (DOT) was maintained at 30%, and pH was
maintained at 6.95 using 50% (w/v) ammonia solution and
20% (v/v) H2SO4 and temperature at 30 °C. After 32 h, the
temperature was reduced to 25 °C. Glycerol feeds, Mg2+, and
PO4
2− were added to the culture at certain intervals. After
approximately 36 h, the production of A33Fab was induced by
the addition of 40 mM of IPTG. The culture was harvested 36
h after induction and cells recovered using a Carr Powerfuge P6
centrifuge (Carr Centritech Separation Systems, Clearwater,
FL, USA) and stored at −80 °C.
A33Fab Extraction and Puriﬁcation. Cells were
resuspended in 100 mM Tris/10 mM EDTA solution, pH
7.4 and incubated overnight at 60 °C at 150 rpm. A
centrifugation step (1h30, 13 000 rpm) followed, and the
A33Fab-rich supernatant was collected for puriﬁcation. A33Fab
was puriﬁed using the AKTA puriﬁer FPLC system. Sepharose
fast ﬂow protein G resin (GE healthcare) was packed in an
XK16 column and equilibrated with 25 mM sodium phosphate,
pH 7.4. The ﬁltered heat lysate was passed through the column,
and the elution was carried out with 60 mM sodium citrate, pH
3.4. An additional gel ﬁltration step (HiLoad Superdex, GE
Healthcare) was done in PBS, pH 7.4 to ensure high purity of
the protein as a monomer as shown in SI1.
Sample Preparation. The puriﬁed A33Fab was dialyzed
overnight at 4 °C in ultrapure water using Dialysis Cassettes,
10K MWCO (Thermo Scientiﬁc) and its concentration
adjusted to 2 mg/mL. Prior to incubation, samples were
diluted to a ﬁnal concentration of 1 mg/mL with the desired
buﬀer. Buﬀers used in this study included 20 mM sodium
citrate for pH 3.5, 4.5, and 5.5; 10 mM sodium phosphate for
pH 7; and 20 mM Tris for pH 8 and pH 9, ensuring an
equivalent maximum contribution to ionic strength from each
buﬀer of 20 mM. Sodium chloride was included to give ﬁnal
ionic strengths for buﬀer and salt combined, ranging between
20 and 500 mM. The lower ionic strength of 7 mM at pH 3.5
was achieved using 7 mM sodium citrate. The lower ionic
strengths of 5 mM at pH 8 and 1 mM at pH 9 were achieved
using 10 mM Tris.
Thermal Stability Studies. The midpoints of thermal
transitions (Tm,app) of A33Fab in various formulations were
determined by monitoring the intrinsic ﬂuorescence using the
Optim1000 (Unchained Laboratories, Wetherby, UK) with
samples ramp-heated from 20 to 90 °C (1 °C/min, including
30 s for measurement at each temperature). A typical
ﬂuorescence intensity curve and associated emission wave-
length scans are shown in SI2. The ratio of the ﬂuorescence
intensity emission at 350 and 330 nm as a function of
temperature was used to determine the Tm,app for the transition
between the folded and the unfolded state by ﬁtting the data to
a two-state model40 using the following equation:
= + + + − +
+ −
I I aT
I bT I aT
T T m
( )
( )
1 exp[ / ]T N
D N
m,app (1)
where IT is the observed signal, IN and ID are the native and
denatured baseline intercepts, a and b are the native and
denatured baseline slopes, T is the temperature, and Tm,app is
the midpoint of the thermal transition. A two-state ﬁt was used
as this gave the simplest ﬁt to the data. It is assumed that a
rapid pre-equilibrium for protein unfolding exists prior to a
relatively slow aggregation step. Thus, the aggregation rate
increases with temperature and only approaches the time scale
of the thermal ramping experiment as the temperature
approaches the Tm, where the protein becomes signiﬁcantly
unfolded. Therefore, Tm,app is closely linked to Tm but is also
convoluted with a term that depends on the aggregation rate
and experimental thermal ramping rate.
The apparent mole-fraction, fapp, of unfolded protein was
calculated at relevant temperatures from
= − − + − −f I I bT I aT I bT( )/( )Tapp D N D (2)
The onset aggregation temperature (Tagg) was also
determined as the point at which 10% increase in the light
scattering at 266 nm occurs relative to the low-temperature
baseline. All measurements were repeated at least three times.
Circular Dichroism. The UV and CD absorption spectra of
A33Fab were acquired on an Applied Photophysics Chirascan
Plus spectropolarimeter (Leatherhead, UK). The 1.0 mm and
0.5 mm Suprasil rectangular cells (Hellma UK Ltd.) were used
in the region 400−190 nm, and the following parameters were
employed: 2 nm spectral bandwidth, 1 nm step size, and 1 s
instrument time per point. UV and CD absorption spectra were
buﬀer baseline corrected. Protein concentration was then
calculated based upon the A280 and the Beer−Lambert law. The
far-UV CD spectra were corrected for concentration and path
length and expressed in terms of Δε (M−1 cm−1) per amino
acid residue (MW = 113). Protein secondary structure contents
were assessed using the Principle Component Regression
method based upon 16 known protein structures41 embedded
in the PLSPlus/IQ routine on GRAM32 AI software. For the
thermal stability, the far-UV CD spectra of A33Fab were ﬁrst
recorded at room temperature (20 °C), cooled to 6 °C, then
heated to high temperature (90 °C) and recooled to 20 °C after
heating. The multiwavelength melting proﬁles, monitored at λ
(260−190 nm), were recorded during the heating process. The
instrument was equipped with a Quantum NorthWest TC125
Peltier unit set to change temperature from 6 to 90 °C at 1 °C
per minute rate with a 2 °C step size. Thus, after 20 s of
temperature ramping by 2 °C, the wavelength scan takes 100 s
to complete using 1.42 s time-per-point CD measurement time
and 1 nm step-size for 260−190 nm, with a 2 nm Spectral
Bandwidth. A 0.5 mm path length rectangular cell was
employed. The temperature was measured directly with a
thermocouple probe in the sample solution. Melting temper-
atures were ﬁtted using a Levenberg−Marquardt algorithm
(LMA) on the van’t Hoﬀ isochore.42
Aggregation Kinetics. The samples were incubated at 4
°C, 23 °C, 45 °C, and 65 °C in glass vials with appropriate solid
caps to minimize evaporation. Aliquots were taken at regular
intervals, and the aggregation was quenched by placing the
samples in ice and followed by centrifugation at 13 000 rpm for
45 min to remove any insoluble aggregates. A33Fab monomer
loss was monitored by SEC-HPLC using a Zorbax-GF250
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.5b00387
Mol. Pharmaceutics 2016, 13, 307−319
309
Figure 1. A33Fab thermal stability. (A) Midpoints of thermal transitions determined by intrinsic ﬂuorescence at pH 3.5 to pH 9, ionic strength (IS)
0−500 mM, at 1 mg/mL A33 Fab. Error bars are shown. (B) CD spectra of A33Fab at 0.2 mg/mL collected at 20 °C at pH 3.5 to pH 4.5 (left) and
pH 5.5 to pH 9 (right). (C) CD melting spectra at 20 °C, 65 °C, 85 °C, and after cooling back to 20 °C, at 0.2 mg/mL A33 Fab.
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column and a 1200 HPLC Agilent system. Sodium phosphate,
200 mM, pH 7 was used as a mobile phase. The elution proﬁle
was observed at an absorbance of 220 and 280 nm. Peak areas
were calculated by manual integration. Initial rates of
aggregation (v) were determined directly from a linear ﬁt of
the time-dependent peak-area data to the ﬁrst 20% of monomer
loss. All experiments were carried out in triplicate.
ThT Kinetics Assays. ThioﬂavinT (ThT) ﬂuorescence in
the presence of A33Fab was obtained during isothermal
incubation with an Optim445 (Unchained Laboratories,
Wetherby, UK). ThT (Sigma, UK) was used at a ﬁnal
concentration of 50 μM, excited at 445 nm, and the
ﬂuorescence signal recorded at 490 nm. All kinetic measure-
ments were carried out in a ﬁnal volume of 9 μL in triplicates
with a ﬁnal A33Fab concentration of 1 mg/mL.
Static Light Scattering and Intrinsic Fluorescence. The
light scattering signal intensity at 266 nm of Fab samples was
collected simultaneously during both the ThT ﬂuorescence
experiments on the Optim445 and the intrinsic ﬂuorescence
measurements on the Optim1000 (Unchained Laboratories,
Wetherby, UK). All kinetic measurements were carried out in a
ﬁnal volume of 9 μL in triplicates with a ﬁnal A33Fab
concentration of 1 mg/mL. Fluorescence intensity kinetics of
unfolding at pH 3.5 was ﬁt to a single exponential equation
after the initial change due to thermal equilibration on the
instrument and sample.
Isoelectric Point Prediction. The homology model for
A33Fab was constructed from the humanized anti-IFN-gamma
Fab crystal structure PDB 1T3F43 using SWISS MODEL
software.44 The isoelectric point (pI) was predicted using the
online algorithm PROPKA 3.0 for protein only.45
Transmission Electron Microscopy (TEM). A33Fab
samples were incubated at 65 °C, pH 3.5 and pH 9, and
each at ionic strengths of both 50 mM and 150 mM. The
samples were collected at various times of the kinetics for TEM
observations. Approximately 2 μL of freshly aggregated sample
was placed dropwise onto carbon Formvar coated 400 mesh
copper grids before partial air drying and blotting with ﬁlter
paper. The grids were subsequently washed with ultrapure
water before negative staining for 30 s with 0.2 μm ﬁltered
uranyl acetate (2% w/v), blotting, and air-drying. Images were
captured at room temperature using a JEOL-1010 transmission
electron microscope (Tokyo, Japan), operating at 80 kV,
equipped with a side-mounted Gatan Orius CCD digital
camera.
■ RESULTS AND DISCUSSION
Apparent Conformational Thermal Stability. The
apparent thermal conformational stability of A33Fab was
investigated by simultaneously monitoring intrinsic ﬂuores-
cence and static light scattering at 266 nm, from which the
thermal transition midpoint (Tm,app) and the aggregation onset
temperature (Tagg) were determined, respectively. As shown in
Figure 1, panel A, Tm,app values ranged between 59.7 and 83.1
°C consistent with apparent transition temperatures for other
Fab proteins, as determined by CD,23,36 DSC,23,46−51 DSF,51
and intrinsic ﬂuorescence.51 An increased apparent conforma-
tional stability (Tm,app > 75 °C) for A33Fab was observed at pH
values above pH 5, where increasing the ionic strength with
NaCl (up to 500 mM) had only minor eﬀects on the Tm,app.
This was in contrast to a destabilization by NaCl at low pH,
which resulted in Tm,app values < 75 °C. These data were
generally consistent with previous reports for IgG1s,14 and also
for a recombinant humanized Fab fragment,36 except that
Wang et al.36 reported that the conformational stability of their
Fab increased with salt concentration (from 0 to 2 M). It
therefore appears that the speciﬁc eﬀect of ionic strength on
apparent conformational stability is Fab-dependent and not
generalizable. Interestingly, low pH formulations in our study
showed a signiﬁcantly higher apparent conformational stability
in the complete absence of added NaCl, with a Tm,app of 73.1
and 83.1 °C, at pH 3.5 and pH 4.5, respectively (Figure 1A). A
similar overall trend was observed when monitoring the
aggregation onset temperature (Tagg) by static light scattering
at 266 nm (SI3), which also conﬁrmed that all thermal melts
induced rapid aggregation.
The secondary structure of A33Fab was also monitored by
circular dichroism (CD) as shown in Figure 1, panels B and C.
CD spectra recorded immediately after equilibration into new
buﬀers at 20 °C (Figure 1B) conﬁrmed that all pH values and
total ionic strength (IS) up to 100 mM retained the same
degree of structure and that this was consistent with the
expected native Fab structure (36% β-sheet content).36,52,53
The multiwavelength melting proﬁles recorded between 6 and
90 °C were used to monitor the changes of Fab secondary
structure in various formulations (Figure 1C and SI4). The CD
melting proﬁles at 220 nm (SI5A) gave CD Tm,app-values that
correlated well with the ﬂuorescence-based Tm,app-values
(SI5B), although CD Tm,app-values were systematically under-
estimated. The CD spectra at high temperatures were complex
and diﬃcult to deconvolute into secondary structure
components, while the magnitude of ellipticity at 220 nm
also increased as the temperature increased. Simple denatura-
tion to random coil would shift the ellipticity at 220 nm to zero;
hence, the CD measurements at high temperature appear to
have been aﬀected by scatter from subvisible aggregates that
lower the Tm,app-values. Nevertheless, the CD data conﬁrmed
that the secondary structure of A33Fab is more stable at pH 5−
7, consistent with previous observations on a humanized Fab.36
In addition, the absorbance and high voltage (or dynode)
values monitored at 220 nm (SI5A) increased signiﬁcantly for
pH 8 and pH 9 at >70 °C, indicating strong light scattering due
to large particulate aggregation at these conditions. The
samples were also observed to be highly turbid at the end of
the melting experiments at pH 8−9, whereas no visible
aggregates were observed at the other conditions.
The CD spectra showed that A33Fab initially shifts to
structure with increased β-sheet content (at 65 °C) and hence a
stronger signal at 217 nm, but also increased random coil, as
observed from the more negative ellipticity at 200 nm, and
increased scattering due to aggregates as discussed above
(Figure 1C, triangle symbols). The random coil content was
greatest at low pH and 65 °C, where the Tm,app was exceeded
and unfolding continued up to 85 °C. At pH 7−9, the extent of
random coil formation was generally less than at low pH,
although the CD signal was also likely to have been aﬀected by
phase separation to precipitates, observed visually at pH 8−9.
Recooling of samples from 85 °C back to 20 °C resulted in
partial refolding at pH values 3.5−5.5 (Figure 1C, white
symbols), particularly at low salt, but no refolding at pH 7−9
(SI4). This was consistent with the observed precipitation at
the higher pH. Interestingly, Fab partially refolded at pH 3.5
only in the absence of added NaCl (Figure 1C, top panel). The
partial refolding at low pH and the absence of visual
precipitation are likely to have resulted from the increased
electrostatic repulsion between proteins at low pH. However,
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Figure 2. A33Fab aggregation kinetics. (A) Size exclusion chromatogram of A33Fab samples at 1 mg/mL at pH 3.5, 100 mM ionic strength from 2
to 90 min. (B) Monomer peak area over time at pH 3.5, IS 0−250 mM (symbols), and corresponding single exponential ﬁts (lines), (inset) linear
correlation between the initial rate of monomer loss (v) and IS. (C) Surface area plots of A33Fab monomer loss rates (v) as a function of pH and IS
determined from SEC-HPLC kinetics at 4 °C, 23 °C, 45 °C, and 65 °C. (D) Aggregation kinetics monitored by ThT ﬂuorescence (black), static
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partial refolding is retained at 100 mM ionic strength for pH 4.5
but not pH 3.5, indicating that the decreased conformational
stability at pH 3.5 relative to that at pH 4.5 is also a factor.
Overall, the thermal stability analyses show that the
propensity of A33Fab to aggregate under thermal denaturation
is pH and ionic-strength dependent, with a stronger
destabilizing eﬀect of ionic strength at low pH. In the absence
of salts, A33Fab molecules appear to be colloidally protected
from aggregation due to the strong electrostatic repulsions at
low pH. Additionally, there may be fewer intact salt bridges at
low pH than at higher pH, making the native conformation
more susceptible to destabilization by salt.
Aggregation Kinetics. The kinetics of A33Fab monomer
loss were obtained by SEC-HPLC over the same range of pH
and ionic strength as described above, at 4 °C, 23 °C, 45 °C,
and 65 °C. The A33Fab monomer eluted at 2.6 mL at a ﬂow-
rate of 1 mL/min. The change in peak area was monitored in
samples incubated in clinical grade stoppered-glass vials until
fully degraded, otherwise for over 1 year at 4 and 23 °C. Figure
2, panel A shows the A33Fab kinetics monitored by SEC-
HPLC at pH 3.5, 0 to 250 mM ionic strength, and 65 °C as an
illustrative example of the analysis carried out in this study.
Extreme care was taken with the use of adequate screw caps to
minimize evaporation. Evaporation was only observed after at
least 6 months of storage, at 45 °C, and only then in occasional
vials that were removed from the study.
The kinetic data were ﬁtted linearly to obtain rates (v) for the
ﬁrst 20% of A33Fab monomer loss. Typical decay curves are
shown in Figure 2, panel B at pH 3.5, 65 °C, and summarized
for 4 °C, 23 °C, 45 °C, and 65 °C in Figure 2, panel C. The
minimum rate observable to 95% conﬁdence by our analysis
had ln(v) ≤ −5.9 (v in % day−1), which corresponded to
approximately 1% monomer loss over 1 year. All data obtained
at 23 °C, 45 °C, and 65 °C were above this limit of detection,
and only four out of 25 data points at 4 °C were at or below the
limit of detection.
No lag-phase was observed for the rate of monomer loss
under any of the conditions studied, indicating that monomer
degradation was not accelerated at any point by the formation
of a critical concentration of nuclei or other intermediate
species. A linear correlation was observed between the rate of
monomer loss and the ionic strength at pH 3.5, 65 °C (Figure
2B, inset) and also at most other conditions explored in this
study (SI6). This salt dependence was strongest at low pH (pH
3.5 and pH 4.5), in agreement with that observed for the
thermal stability of A33Fab (Figure 1A). Also in agreement at
pH 3.5 and pH 4.5 was the sharp deviation to 0 mM NaCl (7
mM and 20 mM ionic strengths respectively), where the rate of
monomer loss was considerably lower than expected, and the
Tm,app considerably higher than expected, from the respective
linear dependencies at higher salt.
Figure 2, panel C summarizes the eﬀects of pH and buﬀer
ionic strength on A33Fab rate of monomer loss for incubations
at 4 °C, 23 °C, 45 °C, and 65 °C. Rates of monomer loss
generally increased with temperature, as expected.24 Indeed, the
half-life of A33Fab was 5 years at pH 3.5, 250 mM ionic
strength at 4 °C, but only 2 min when incubated at 65 °C.
Figure 2, panel C also shows that low pH formulations (pH 3.5
and pH 4.5) were more prone to aggregation at all
temperatures, except in the absence of salts at high temper-
atures where strong electrostatic repulsions (calculated net
charges of +41.8 and +27.7 at pH 3.5 and pH 4.5, respectively)
appear to protect the Fab from aggregating. This is consistent
with the salt dependence of Tm,app in Figure 1, panel A, and
both suggest that these electrostatic eﬀects were screened out at
100 mM ionic strength and above for pH 3.5, and by only 50
mM and above for pH 4.5. These observations were also
consistent with a previous study on IgG1 in which repulsive net
charges at low pH increased the colloidal stability.20 A33Fab
exhibited the greatest stability to monomer loss at pH 5.5−7, in
agreement with the apparent conformational stability (Tm,app)
reported above. The rate of A33Fab monomer loss increased at
above pH 7 as the pH approached the isoelectric point (pI
8.41). While broadly similar, the proﬁles at each temperature
were not identical, suggesting that forced degradation kinetics
at 45 or 65 °C does not accurately predict the same rank order
of conditions that lead to the least aggregation at 23 or 4 °C.
A33Fab aggregation kinetics was also monitored using
intrinsic ﬂuorescence, ThioﬂavinT (ThT) ﬂuorescence, and
static light scattering at 266 nm (SLS266 nm) at pH 3.5, 4.5,
and 9, at 65 °C, where the faster rates of aggregation and
monomer loss were on time scales amenable to isothermal
incubations and continual monitoring within the instrument
itself. Intrinsic ﬂuorescence intensity can be aﬀected by tertiary
structure unfolding as well as by the decrease in absorbable
photons due to elastic light scattering by aggregates, and so this
was also used to assess the rate of Fab unfolding or aggregation,
as determined by the ratio of ﬂuorescence intensities at 350 and
330 nm.54 At pH 3.5, 65 °C, the kinetics measured by intrinsic
ﬂuorescence for A33Fab (SI7) was biphasic. The fast phase
occurred on the same time scale as monomer loss by SEC,
consistent with rapid protein unfolding at these conditions. For
the slower phase at pH 3.5, 65 °C, the extent and rate of change
of intrinsic ﬂuorescence clearly increased with ionic strength,
and the half-life ranged from >10 to 1 h, for 50 and 200 mM
ionic strength, respectively. At pH 9, the initial change in
intrinsic ﬂuorescence was not dependent on ionic strength, and
the half-life was about 4 h at 65 °C and 10 h at 45 °C,
coincident with the monomer loss measured by SEC at pH 9.0.
By comparison, no signiﬁcant change was observed at pH 3.5 at
45 °C or at pH 4.5 over the ﬁrst 40 h at 65 °C or 120 h at 45
°C (SI7), indicating that the protein did not unfold under these
conditions.
As shown in Figure 2, panel D, both ThT and SLS266 nm
signals increased over time when A33Fab was incubated at pH
3.5, 65 °C in the presence of salts, suggesting the formation of
larger (>100 nm) aggregates with increased intermolecular β-
sheet structure.55 Previous studies have reported that ThT
binds strongly to some IgG1 aggregates,14,19,56 but not for all
IgG1 molecules.14,19,56 Increased ThT ﬂuorescence can indicate
binding to amyloid-like ﬁbrils, or less ordered aggregates with
increased intermolecular β-sheet structure,56 but can also
potentially result from nonspeciﬁc binding to certain protein
surface features formed by tyrosine residues.57 Either way, the
contrasting behaviors of diﬀerent aggregated antibodies suggest
that there can be distinguishable diﬀerences within the structure
Figure 2. continued
light scattering 266 nm (blue), and SEC-HPC (red). (E) TEM of A33Fab incubated at 65 °C (top panel) until 20% monomer loss at pH 3.5 (left)
and pH 9 (right) at 50 mM ionic strength. (Lower panel) TEM of A33Fab incubated 1 h (left) and 8 h (right) at pH 3.5, 150 mM IS.
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of IgG aggregates that may be either IgG or aggregation
condition dependent.
The ThT signal showed no clear lag-phase, and the initial
rate of ThT signal formation was signiﬁcantly slower than
though linearly proportional to the rate of monomer loss
measured by SEC. It was also linearly proportional to and on
the same time scale as the slow-phase rate of change observed
by intrinsic ﬂuorescence (SI8). This indicated that these events
were directly linked such that the ThT signal increase, and the
slow-phase intrinsic ﬂuorescence change resulted from an
aggregated state that forms more slowly than protein unfolding
and the loss of native monomer. Overall, increasing [NaCl] at
pH 3.5, 65 °C led to faster protein unfolding (measured by the
intrinsic ﬂuorescence fast-phase), faster monomer loss (meas-
ured by SEC), and then a more rapid formation of aggregates as
measured by the slow-phase in intrinsic ﬂuorescence and by
ThT binding (Figure 2D).
It was also clear that the ThT signal increased prior to that of
the static-light scattering, for which a lag-phase could be
observed at 150 mM and 200 mM ionic strength. The lag phase
observed by SLS at higher salt indicated that a second, larger
aggregate population is formed either by nucleation onto or
condensation of the intermediate aggregates, giving the ThT
binding signal such that SLS detects only the subsequent larger
aggregate. A low population of soluble oligomeric states was
also observed by SEC-HPLC (Figure 2A, inset). The ﬁnal ThT
signal decreased as the ionic strength increased from 100 mM
to 200 mM, whereas the ﬁnal SLS266 nm signal increased,
which is consistent with either a ﬁnal equilibrium between the
ThT-ﬂuorescent intermediate aggregate and the larger light-
Figure 3. Correlation to the initial rates for monomer loss ln(v) and the midpoints of thermal transitions (Tm,app) at (A) 4 °C, (B) 23 °C, (C) 45 °C,
and (D) 65 °C and to (E) the mole-fraction of unfolded protein ( fapp). Formulations range between pH 3.5 and pH 9, ionic strength from 1 mM to
500 mM.
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scattering aggregates or a kinetic partitioning that is ionic-
strength dependent.
ThT was also able to detect A33Fab aggregation at pH 4.5,
65 °C (SI9), whereas no increased ﬂuorescence signal from
ThT could be detected at pH 9.0, 65 °C, possibly due to their
rapid onward conversion, the formation of diﬀerent aggregate
forms, or to the hydroxylation of the ThT dye at basic pH.58 As
the monomer loss observed by SEC at pH 9.0 occurs at the
same time as both the increases in intrinsic ﬂuorescence and
SLS266 nm signals, with no observable ThT signal increase, the
intermediate aggregate observed at pH 3.5, 65 °C does not
appear to populate at pH 9.0, and the monomer appears to
convert rapidly into large aggregates.
The morphology of A33Fab aggregates generated at pH 3.5
and pH 9.0, at 65 °C were examined by TEM (Figure 2E). At
pH 3.5 after 20% monomer loss (5 min at 65 °C), the
aggregates appeared as elongated worm-like oligomers of about
10 nm width and up to 100 nm in length (Figure 2E, top left,
arrows). These worm-like species were not observed directly by
SEC, indicating that they are suﬃciently large to be ﬁltered out
at the entrance to the column. They were also not suﬃciently
large (100 nm) to result in signiﬁcant light scattering at 266
nm. By contrast, the aggregates formed at pH 9 after 20%
monomer loss (11 days at 65 °C) were bigger and more
amorphous. When incubated for a longer time at pH 3.5, the
population of elongated oligomers increased concomitant with
the ThT-signal increase (Figure 2E, lower left, arrows) and
eventually resulted in their coalescence into larger aggregates,
consistent with the increase in SLS266 nm signal (Figure 2E,
lower right panel). It appears then that while these aggregates
lacked any highly ordered ﬁbrillar structural features, the ThT
signal increase was linked to the formation of an elongated
Figure 4. Arrhenius plots for A33Fab formulations from pH 3.5 to pH 9 and IS from 0 mM to 500 mM.
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oligomer that was only partially ordered and perhaps contained
some amyloid-like attributes. Similar “worm-like” semiﬂexible
ﬁbrils were reported for β2-microglobulin and formed via a
pathway distinct from that leading to the formation of amyloid
ﬁbrils under diﬀerent solution conditions.59 Here, we also
report two distinct aggregation pathways at low and high pH
(at 65 °C), whereby semiordered worm-like species that bind
ThT form at low pH only, which then appear to either nucleate
or condense into larger aggregates. Interestingly, the β2-
microglobulin worm-like ﬁbrils were also reported to bind to
ThT, and recent NMR data showed that they exhibit an
ordered β-sheet core.60 By contrast, large amorphous
aggregates formed at pH 9 (at 65 °C) with no observable
binding to ThT.
Conformational Stability: A Predictor of Aggregation
Kinetics? The stability and the aggregation propensities of
A33Fab were monitored by intrinsic ﬂuorescence (Tm,app),
static light scattering (Tagg), and SEC-HPLC (v) at a wide range
of pH, ionic strength, and temperature as described above. To
determine whether the apparent conformational stability of
A33Fab was correlated to the aggregation kinetics, the initial
rates of monomer loss (ln v) were plotted as a function of
Tm,app for all the formulations at each incubation temperature
(Figure 3). A linear correlation was observed for the kinetics at
65 °C, with an apparent kink within the pH 4.5 conditions,
separating the formulations containing NaCl at pH 3.5 from the
remaining conditions (Figure 3D). In the presence of NaCl at
pH 3.5, the incubation temperature of 65 °C was above the
Tm,app, resulting in the irreversible unfolding of the protein as
observed by CD (Figure 1C) and intrinsic ﬂuorescence (SI7).
Therefore, the distinct kink in the correlation was likely due to
a shift toward aggregation from the unfolded state at pH 3.5
and 50−250 mM ionic strength. Under these conditions (above
the Tm,app), both native and unfolded states would be highly
protonated (+41.8 for the native state at pH 3.5). Therefore,
colloidal electrostatic repulsion between protein molecules
would strongly increase and act to protect them from
aggregation, contributing to the lower than expected ln v at
pH 3.5, 65 °C and the kink in Figure 3, panel D. This is also in
agreement with the work reported by Menzen et al.20 in which
the repulsive net charge at low pH was shown to increase the
colloidal stability of IgG1 even though a reduction of the
conformational stability was also observed.
No kink was observed in the kinetics at 45 °C (Figure 3C),
23 °C (Figure 3B), or 4 °C (Figure 3A). The linear correlation
between ln(v) and Tm,app was also present at 45 °C, though
weaker than at 65 °C. At 23 and 4 °C, there was no longer an
observable dependency of the rate of monomer loss on Tm,app.
A similar analysis was attempted between Tagg and t1/2, but no
correlation could be found (data not shown). Overall, the Tm,app
of A33Fab correlated with the rate of monomer loss, but only
when the incubation temperature was close to the Tm,app. It is
possible that there was a small correlation to Tm,app at low
temperatures, but if any such correlation exists, it must be
below the statistical resolution of our kinetic measurements.
To analyze the relative impact of protein unfolding, the
apparent mole-fraction, fapp, of unfolded protein was estimated
from the thermal melting proﬁles and compared to the initial
rates of monomer loss (Figure 3E). A signiﬁcant population of
unfolded protein was observed only at 65 °C, and then only at
pH 8 and 9 (0.4−1.5% unfolded), and at pH 3.5 and 4.5
(>1.5% unfolded in the presence of NaCl), consistent with the
CD (Figure 1C) and intrinsic ﬂuorescence (SI7). The proﬁle
obtained was sigmoidal, with a transition to a signiﬁcantly faster
rate of monomer loss at pH 3.5 in the presence of NaCl. This
indicated aggregation from a structured state at low temper-
atures, with a shift in mechanism toward aggregation from the
unfolded state in low pH at 65 °C. Partial unfolding to native-
like monomers, prior to protein aggregation, has been
proposed13 and reported previously for various proteins
including IgGs61 amyloidogenic proteins such as prion15 and
α-synuclein16 and the SH3 domain.62 Future work will attempt
to directly characterize whether such partially unfolded
monomeric states inﬂuence the aggregation kinetics for
A33Fab.
While an overall temperature dependence of ln v is evident in
Figure 3, panel E, between the 4 °C, 23 °C, and 65 °C
conditions, the sensitivity of ln v to fapp, in these conditions is
low, consistent with the observations for Tm,app in Figure 3,
panels A−D. Such a loss of sensitivity to Tm,app or fapp, as the
incubation temperature was decreased, suggests that the global
conformational stability of the native state, which is measured
relative to the unfolded state, is not a major contributing factor
to the aggregation propensity under these conditions. The use
of Tm,app for formulation screening appeared to be limited in
use for the case of A33Fab, ensuring that aggregation from the
unfolded state was not signiﬁcant. It did not appear to be a
good indicator for rank ordering the ability of A33Fab
formulations to minimize monomer loss during incubation at
the lower temperatures, as relevant to biopharmaceutical
storage.
Does Aggregation of Fab Follow Arrhenius Behavior?
Arrhenius plots of ln(v) versus 1/T at each pH (Figure 4) were
found to be linear at all pH, except under conditions where the
protein was signiﬁcantly unfolded, that is, for pH 3.5 or 4.5, at
65 °C, in the presence of NaCl. The Arrhenius plots were also
slightly curved at pH 9 due to the higher rate at 65 °C, which
likely results from the 0.8−1.5% mole-fraction of unfolded
protein at these conditions. Similar non-Arrhenius observations
have been reported previously for monoclonal IgG1 antibod-
ies,63,64 where ﬁtting of the data to modiﬁed Arrhenius
equations enabled empirical models to be created that could
be used to predict low temperature aggregation rates from high
temperature data. Such behavior was also attributed to an
increased population of the unfolded state.
While Arrhenius behavior was observed over the 4−45 °C
range, comparison of the proﬁles of monomer loss rates in
Figure 2, panel C, and a direct comparison in SI10, suggest that
the rank order of conditions at 45 °C do not predict well those
at 4 °C. This could result from a complex dependence on pH
and ionic strength for the slopes of the Arrhenius plots with
A33Fab and cannot simply be accounted for by statistical errors
in the data (SI10).
■ SUMMARY
Overall, our results suggest that the aggregation kinetics of
A33Fab only appear to correlate strongly with conformational
stability, as measured by Tm,app, at temperatures that approach
the Tm,app. Tm,app was therefore not a strong indicator for
predicting A33Fab aggregation rates at low temperatures. At
elevated temperatures, protein aggregation from the unfolded
state began to dominate as it became populated, whereas
aggregation was from a structured monomeric state at lower
temperatures and was not strongly dependent on the mole
fraction of globally unfolded protein. Aggregation from the
unfolded state at low pH and elevated temperatures led to the
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accumulation of soluble 100 nm worm-like aggregates and then
larger insoluble aggregates by nucleation or aggregate-
condensation. A kink in the correlation between rate of
monomer loss at 65 °C and Tm,app was due to low pH and high
ionic strength conditions in which the protein began to unfold
and also would have increased intermolecular electrostatic
repulsion. Similarly complex mechanisms were observed
previously for IgG1,63 and so simplifying the molecular system
to Fab alone does not appear to reduce considerably the
complexity of aggregation mechanisms. Arrhenius behavior was
observed with A33Fab, except under low pH conditions at 65
°C where aggregation from the unfolded state predominated.
However, the rank order of rates of monomer loss for the
formulations at 45 °C did not predict those at 4 °C, as the
slopes of Arrhenius plots were also dependent on solution
conditions. Instead, a robust and accurate extrapolation to rates
at 4 °C would require rate measurements in every formulation
across a wide range of temperatures.
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■ NOTE ADDED AFTER ASAP PUBLICATION
This Article was published ASAP on January 4, 2016, with an
error in equation 1. The corrected version was reposted on
January 6, 2016.
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